Pfizer to Acquire Global Blood Therapeutics, Achieves Long-Time Goal
Pfizer is acquiring Global Blood Therapeutics in a deal valued at $5.4 billion, which helps Pfizer realize its long-time goal of having a sickle-cell disease portfolio.
The latest news in the healthcare sector including biotech and telehealth.